Relationship between serum triglyceride levels and endothelial function in a large community-based study

Atherosclerosis

Volumn 249, Issue , 2016, Pages 70-75

  Kajikawa, Masato ^a   Maruhashi, Tatsuya ^b   Matsumoto, Takeshi ^b   Iwamoto, Yumiko ^b   Iwamoto, Akimichi ^b   Oda, Nozomu ^b   Kishimoto, Shinji ^b   Matsui, Shogo ^b   Aibara, Yoshiki ^c   Hidaka, Takayuki ^b   Kihara, Yasuki ^b   Chayama, Kazuaki ^b   Goto, Chikara ^d   Noma, Kensuke ^a,c   Nakashima, Ayumu ^a   Tomiyama, Hirofumi ^e   Takase, Bonpei ^f   Yamashina, Akira ^e   Higashi, Yukihito ^c  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Atherosclerosis; Endothelial function; Triglycerides

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTERY DIAMETER; ARTICLE; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FLOW MEDIATED VASODILATION; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; JAPAN; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; RISK FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; JAPAN; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TRIGLYCERIDES; VASODILATION;

EID: 84962710453     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.03.035     Document Type: Article

References (42)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
2. Higashi Y., Noma K., Yoshizumi M., Kihara Y. Oxidative stress and endothelial function in cardiovascular diseases (review). Circ. J. 2009, 73:411-418.
3. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
4. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 1994, 24:1468-1474.
5. Benjamin E.J., Larson M.G., Keyes M.J., Mitchell G.F., Vasan R.S., Keaney J.F., Lehman B.T., Fan S., Osypiuk E., Vita J.A. Clinical correlates and heritability of flow-mediated dilation in the community: the framingham heart study. Circulation 2004, 109:613-619.
6. Maruhashi T., Soga J., Idei N., Fujimura N., Mikami S., Iwamoto Y., Kajikawa M., Matsumoto T., Kihara Y., Chayama K., Noma K., Nakashima A., Tomiyama H., Takase B., Yamashina A., Higashi Y. Hyperbilirubinemia, augmentation of endothelial function and decrease in oxidative stress in Gilbert syndrome. Circulation 2012, 126:598-603.
7. Kajikawa M., Nakashima A., Fujimura N., Maruhashi T., Iwamoto Y., Iwamoto A., Matsumoto T., Oda N., Hidaka T., Kihara Y., Chayama K., Goto C., Aibara Y., Noma K., Takeuchi M., Matsui T., Yamagishi S., Higashi Y. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care 2015, 38:119-125.
8. Matsumoto T., Oki K., Kajikawa M., Nakashima A., Maruhashi T., Iwamoto Y., Iwamoto A., Oda N., Hidaka T., Kihara Y., Kohno N., Chayama K., Goto C., Aibara Y., Noma K., Liao J.K., Higashi Y. Effect of aldosterone-producing adenoma on endothelial function and rho-associated kinase activity in patients with primary aldosteronism. Hypertension 2015, 65:841-848.
9. Kajikawa M., Nakashima A., Maruhashi T., Iwamoto Y., Iwamoto A., Matsumoto T., Hidaka T., Kihara Y., Chayama K., Goto C., Taguchi A., Noma K., Higashi Y. Poor oral health, that is, decreased frequency of tooth brushing, is associated with endothelial dysfunction. Circ. J. 2014, 78:950-954.
10. Adams M.R., Robinson J., McCredie R., Seale J.P., Sorensen K.E., Deanfield J.E., Celermajer D.S. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 1998, 32:123-127.
11. Raitakari O.T., Seale J.P., Celermajer D.S. Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. Am. J. Cardiol. 2001, 87:217-219. A8.
12. Modena M.G., Bonetti L., Coppi F., Bursi F., Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J. Am. Coll. Cardiol. 2002, 40:505-510.
13. Gokce N., Keaney J.F., Hunter L.M., Watkins M.T., Menzoian J.O., Vita J.A. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002, 105:1567-1572.
14. Brevetti G., Silvestro A., Schiano V., Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003, 108:2093-2098.
15. Lerman A., Zeiher A.M. Endothelial function: cardiac events. Circulation 2005, 111:363-368.
16. Yeboah J., Folsom A.R., Burke G.L., Johnson C., Polak J.F., Post W., Lima J.A., Crouse J.R., Herrington D.M. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106. 3143-3421.
18. Sirimarco G., Labreuche J., Bruckert E., Goldstein L.B., Fox K.M., Rothwell P.M., Amarenco P. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 2014, 45:1429-1436. PERFORM and SPARCL Investigators and Committees.
19. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
20. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
21. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., Goldberg A.C., Howard W.J., Jacobson M.S., Kris-Etherton P.M., Lennie T.A., Levi M., Mazzone T., Pennathur S. Triglycerides and cardiovascular disease: a scientific statement from the American heart association. Circulation 2011, 123:2292-2333.
22. Chapman M.J., Ginsberg H.N., Amarenco P., Andreotti F., Borén J., Catapano A.L., Descamps O.S., Fisher E., Kovanen P.T., Kuivenhoven J.A., Lesnik P., Masana L., Nordestgaard B.G., Ray K.K., Reiner Z., Taskinen M.R., Tokgözoglu L., Tybjærg-Hansen A., Watts G.F. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011, 32:1345-1361.
23. Reiner Ž. Are elevated serum triglycerides really a risk factor for coronary artery disease?. Cardiology 2015, 131:225-227.
24. Reiner Ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metab. Cardiovasc Dis. 2013, 23:799-807.
25. Patel A., Barzi F., Jamrozik K., Lam T.H., Ueshima H., Whitlock G., Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110:2678-2686. Asia Pacific Cohort Studies Collaboration.
26. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K.K., Thompson A., Wood A.M., Lewington S., Sattar N., Packard C.J., Collins R., Thompson S.G., Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
27. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
28. Pierce G.L., Beske S.D., Lawson B.R., Southall K.L., Benay F.J., Donato A.J., Seals D.R. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension 2008, 52:72-79.
29. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2014, 37(Suppl. 1):S81-S90.
30. Maruhashi T., Soga J., Fujimura N., Idei N., Mikami S., Iwamoto Y., Kajikawa M., Matsumoto T., Hidaka T., Kihara Y., Chayama K., Noma K., Nakashima A., Goto C., Higashi Y. Nitroglycerine-induced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1401-1408.
31. West K.M., Ahuja M.M., Bennett P.H., Czyzyk A., De Acosta O.M., Fuller J.H., Grab B., Grabauskas V., Jarrett R.J., Kosaka K. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983, 6:361-369.
32. Bitzur R., Cohen H., Kamari Y., Shaish A., Harats D. Triglycerides and HDL cholesterol: stars or second leads in diabetes?. Diabetes Care 2009, 32(Suppl. 2):S373-S377.
33. Rapp J.H., Lespine A., Hamilton R.L., Colyvas N., Chaumeton A.H., Tweedie-Hardman J., Kotite L., Kunitake S.T., Havel R.J., Kane J.P. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 1994, 14:1767-1774.
34. Schwartz E.A., Reaven P.D. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim. Biophys. Acta 2012, 1821:858-866.
35. Van Eck M., Zimmermann R., Groot P.H., Zechner R., Van Berkel T.J. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2000, 20:E53-E62.
36. Palmer A.M., Murphy N., Graham A. Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis 2004, 173:27-38.
37. Patel S., Puranik R., Nakhla S., Lundman P., Stocker R., Wang X.S., Lambert G., Rye K.A., Barter P.J., Nicholls S.J., Celermajer D.S. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 2009, 204:424-428.
38. Pauletto P., Puato M., Caroli M.G., Casiglia E., Munhambo A.E., Cazzolato G., Bittolo Bon G., Angeli M.T., Galli C., Pessina A.C. Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania: the Lugalawa study. Lancet 1996, 348:784-788.
39. He Y., Lam T.H., Li L.S., Li L.S., He S.F., Liang B.Q. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann. Epidemiol. 2004, 14:1-7.
40. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D., ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32:1769-1818.
41. Chan D.C., Wong A.T., Yamashita S., Watts G.F. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment. Atherosclerosis 2012, 221:484-489.
42. Sugiura T., Dohi Y., Yamashita S., Yamamoto K., Wakamatsu Y., Tanaka S., Kimura G. Impact of lipid profile and high blood pressure on endothelial damage. J. Clin. Lipidol. 2011, 5:460-466.